Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
JCI Insight|February 20, 2024
Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancerQiang Zhang, Long Jiang, Weiwei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2020
Metastatic Pancreatic Cancer: ASCO Guideline UpdateDavendra P S Sohal, Erin B Kennedy, Pelin Cinar, et al.
The Lancet. Oncology|March 24, 2020
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 studyGhassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
Nature Cancer|April 28, 2026
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancerChengyi Li, Fang Ke, Hongyi Zhao, et al.
JCO Precision Oncology|April 11, 2024
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyVaibhav Sahai, Michael Rothe, Pam K Mangat, et al.
Cell Reports. Medicine|March 25, 2026
Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumorsYizhi Cao, Caleb Cheng, Yitong Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2020
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 MutationEileen M O'Reilly, Jonathan W Lee, Mark Zalupski, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
Spatial analysis of IPMNs defines a paradoxical KRT17-positive, low-grade epithelial population harboring malignant featuresJay Li, Justin Macchia, Ahmed M Elhossiny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2024
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 StudyPhilip A Philip, Vaibhav Sahai, Nathan Bahary, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Longitudinal analysis of matched patient biospecimens reveals Neural Reprogramming of Cancer-Associated Fibroblasts Following Chemotherapy in Pancreatic Ductal AdenocarcinomaAylin Z Henstridge, Nandini Arya, Ahmed M Elhossiny, et al.
Pageof 11